{"protocolSection":{"identificationModule":{"nctId":"NCT07340216","orgStudyIdInfo":{"id":"ARQ-154-127"},"organization":{"fullName":"Arcutis Biotherapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis","officialTitle":"An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% Administered QD in Pediatric Participants With Scalp and Body Psoriasis"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-12-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-12-19","studyFirstSubmitQcDate":"2026-01-05","studyFirstPostDateStruct":{"date":"2026-01-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-05","lastUpdatePostDateStruct":{"date":"2026-01-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Arcutis Biotherapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.","detailedDescription":"ARQ-154-127 is a Phase 1, open-label, single arm, maximum usage pharmacokinetic and safety study of roflumilast foam 0.3% in participants with scalp and body psoriasis.\n\nThe goal of the study is to:\n\n* Evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile of ARQ-154 foam 0.3%.\n* Assess the safety and tolerability of ARQ-154 foam 0.3%"},"conditionsModule":{"conditions":["Psoriasis"],"keywords":["Scalp and Body Psoriasis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":16,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ARQ-154 Foam 0.3%","type":"EXPERIMENTAL","description":"ARQ-154 foam 0.3% will be applied QD. Treatment duration will be up to 6 weeks, including 2 weeks under maximal usage conditions, followed by an optional 4 weeks under non-maximal usage conditions.","interventionNames":["Drug: ARQ-154 Foam 0.3%"]}],"interventions":[{"type":"DRUG","name":"ARQ-154 Foam 0.3%","description":"ARQ-154 Foam 0.3%","armGroupLabels":["ARQ-154 Foam 0.3%"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Concentration of Roflumilast and Roflumilast N-Oxide from plasma","description":"Assessment of steady-state trough plasma concentrations after 2 weeks of study drug administration.","timeFrame":"2 Weeks"},{"measure":"Participant incidence of adverse events","description":"Number of participants with adverse events during treatment will be assessed","timeFrame":"6 Weeks"},{"measure":"Incidence of application site reactions","description":"Number of participants that experience an application site skin reaction by investigator assessment and participant assessment will be assessed","timeFrame":"6 Weeks"},{"measure":"The incidence of changes from Baseline in the total Children's Depression Inventory 2 (CDI-2)score.","description":"The CDI-2 is an assessment instrument used to evaluate the severity of depressive symptoms in children.","timeFrame":"6 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females, ages 2 years to \\< 12 years old at Day 1.\n* Clinical diagnosis of psoriasis vulgaris of at least 2 months duration at Screening as determined by the Investigator.\n* Scalp psoriasis with an Investigator Global Assessment (S-IGA) of scalp disease severity of at least Moderate ('3') at Day 1.\n* An IGA of body (non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Day 1.\n* Extent of scalp psoriasis involving â‰¥ 10% of the total scalp at Day 1.\n* Body psoriasis (non-scalp) involving at least 3% BSA on Day 1.\n\nExclusion Criteria:\n\n* Participants who cannot discontinue medications and treatments prior to Day 1 (first application of IP).\n* Current diagnosis of non-plaque forms of psoriasis. Current diagnosis of drug-induced psoriasis.\n* Participants who have significant active systemic or localized infection or have had any infection that required oral or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days prior to Day 1.\n* Participants with skin conditions other than psoriasis vulgaris that would interfere with evaluations of the effect of the study medication, as determined by the Investigator.\n* Participants who cannot discontinue the use of strong cytochrome P-450 CYP3A4 inhibitors for 2 weeks prior to Day 1 and during the study period.\n* A medical history of severe renal insufficiency, moderate to severe hepatic disorders (e.g., Child-Pugh B or C), or chronic infectious disease (e.g., hepatitis B, hepatitis C, or human immunodeficiency virus \\[HIV\\]).\n* Participants who are family members of the clinical study staff or sponsor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"centralContacts":[{"name":"Arcutis Biotherapeutics","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"locations":[{"facility":"Arcutis Clinical Study Site 106","status":"RECRUITING","city":"Bryant","state":"Arkansas","zip":"72022","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"1-844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":34.59593,"lon":-92.48905}},{"facility":"Arcutis Clinical Study Site 107","status":"RECRUITING","city":"Miami Lakes","state":"Florida","zip":"33014","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":25.90871,"lon":-80.30866}},{"facility":"Arcutis Clinical Study Site 108","status":"RECRUITING","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"Arcutis Clinical Study Site 105","status":"RECRUITING","city":"West Lafayette","state":"Indiana","zip":"47906","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":40.42587,"lon":-86.90807}},{"facility":"Arcutis Clinical Study Site 104","status":"RECRUITING","city":"Arlington","state":"Texas","zip":"76011","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":32.73569,"lon":-97.10807}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D011565","term":"Psoriasis"}],"ancestors":[{"id":"D017444","term":"Skin Diseases, Papulosquamous"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]}},"hasResults":false}